

AD _____

Award Number: DAMD17-96-1-6076

TITLE: Stimulation of p53-Dependent Transcription by the Growth
Suppressor, c-Abl

PRINCIPAL INVESTIGATOR: Xuan Liu, Ph.D.
John Cogan

CONTRACTING ORGANIZATION: University of California Riverside
Riverside, California 92521

REPORT DATE: July 2001

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20020206 119

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)**2. REPORT DATE**

July 2001

3. REPORT TYPE AND DATES COVERED

Final (01 Jul 96 - 31 May 01)

4. TITLE AND SUBTITLE

Stimulation of p53-Dependent Transcription by the Growth Suppressor, c-Abl

5. FUNDING NUMBERS

DAMD17-96-1-6076

6. AUTHOR(S)Xuan Liu, Ph.D.
John Cogan**7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)**University of California Riverside
Riverside, California 92521E-Mail: xuan.liu@ucr.edu**8. PERFORMING ORGANIZATION
REPORT NUMBER****9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)**U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012**10. SPONSORING / MONITORING
AGENCY REPORT NUMBER****11. SUPPLEMENTARY NOTES****12a. DISTRIBUTION / AVAILABILITY STATEMENT**

Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE**13. ABSTRACT (Maximum 200 Words)**

Although it is known that c-Abl stimulates p53-dependent transcription, a function required for c-Abl growth suppressor activity, the molecular mechanism by which this occurs remain elusive. The results obtained with this grant award show that c-Abl interacts with the C-terminal regulatory domain of tetrameric form of p53 and functions to activate the p53 DNA-binding. In an effort to assess the mechanism of c-Abl activation, we also show that c-Abl activates p53 DNA-binding by stabilizing the p53-DNA complex. Collectively, these results suggest a model for c-Abl activation. In this model c-Abl activates latent p53 by relieving the C-terminal inhibitory domain of p53 and enhances p53 DNA-binding by forming a stable p53-DNA complex (see text).

14. SUBJECT TERMS

Breast Cancer

15. NUMBER OF PAGES

17

16. PRICE CODE**17. SECURITY CLASSIFICATION
OF REPORT**

Unclassified

**18. SECURITY CLASSIFICATION
OF THIS PAGE**

Unclassified

**19. SECURITY CLASSIFICATION
OF ABSTRACT**

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

___ Where copyrighted material is quoted, permission has been obtained to use such material.

___ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

___ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.



PI - Signature

9/7/01

Date

Table of Contents

| | |
|--|-----------|
| Cover..... | 1 |
| SF 298..... | 2 |
| Foreword..... | 3 |
| Table of Contents..... | 4 |
| Introduction..... | 5 |
| Body..... | 6 |
| Key Research Accomplishments..... | 10 |
| Reportable Outcomes..... | 11 |
| Conclusions..... | 12 |
| Appendices..... | 12 |
| Bibliography..... | 13 |
| Personnel..... | 17 |

INTRODUCTION

Loss of cell growth regulation is a characteristic of cancer cells. To achieve our goal of designing therapies for cancer, we must understand how cancer proteins affect cell growth. The aim of this proposal is to address this question for the cancer related proteins, p53 and c-Abl. Specifically, we have proposed:

To define the domains on p53 required for c-Abl binding

To examine the effect of c-Abl on the DNA-binding activity of p53

To characterize the effect of c-Abl on p53-dependent transcription *in vitro*

To determine the effect of Gal4-Abl on transcription from a promoter containing Gal4 sites

To examine whether general transcription factors are phosphorylated by c-Abl

PREVIOUS WORK AND ACCOMPLISHMENTS

When this grant was submitted in 1995, we had only a limited understanding of the regulation of p53-mediated transcription by cell cycle proteins. We proposed to study molecular mechanisms by which c-Abl activates p53-mediated transcription as I have observed, while I was a postdoctoral fellow in Arnold Berk's laboratory at UCLA, that c-Abl exhibits an p53-dependent growth suppression and enhances the transcriptional activity of p53 *in vivo*.

To address Specific Aim 1, we performed an extensive deletion and site-specific mutational analysis and showed two regions on p53 that are required for c-Abl interaction, an extreme C-terminal region (aa 363 to 393) and a tetramerization domain (aa 325 to 356). We also constructed a tetramerization impair mutant, 341K344E348E355K and showed that this mutant fails to bind to c-Abl, which demonstrates the requirement of the tetrameric conformation of p53 for c-Abl interaction (Nie et al). The C-terminal region was previously identified as a regulatory domain to inhibit the DNA binding activity of p53. Thus, we proposed a model in which c-Abl interacts with the negative regulatory domain to enhance the DNA binding activity of p53.

To address Specific Aim 2, we obtained highly purified c-Abl protein via a baculovirus expression system and showed that c-Abl stimulates the DNA-binding activity of full-length p53 but not a carboxyl terminal mutant p53, $\Delta 363$. This result suggested that interaction of c-Abl abolished the inhibitory effect of the C-terminal domain. In addition, we studied mechanisms for c-Abl activation and showed that c-Abl stimulates p53's DNA binding by decreasing the dissociation rate of the p53-DNA complex (Nie et al, 2000). The C-terminal regulatory domain was proposed by others to interact with a motif in the core DNA binding domain of the p53 tetramer, thereby forming a conformationally inactive complex. Despite compelling evidence for such a model, the motif on the core domain that interacts with the C-terminus remains to be identified. In addition, the increased association rate of p53 and DNA after disrupting the C-terminal inhibition has never been observed. An alternative explanation, therefore, is that the C-terminal domain may interfere with the tetramerization of p53, resulting in a less stable p53-DNA complex. To support this alternative model (Fig. 1), we first performed analytical ultracentrifugation and showed that interaction with c-Abl stabilized p53 tetrameric conformation. Second, we have shown that c-Abl stimulates p53 DNA binding only when all four quarter-sites on a p53 promoter are present. This was a very significant result to us, raising the possibility that in response to DNA damage, c-Abl may selectively stimulate p53 DNA binding on the promoters that contain four perfect quarter-sites (Wei and Liu, manuscript in preparation).




Figure 1. Proposed model of p53 activation by c-Abl. Green: the tetramer domain of p53; Red: the DNA binding domain of p53. Each arrow represents a quarter-site on a p53 promoter.

The goal of Specific Aim 3 was to study the effect of c-Abl on p53-dependent transcription and on the interaction of p53 with its functional transcription targets. We were hoping to identify p53's functional targets (such as general transcription factors or coactivators) that are responsible for c-Abl activation using a reconstitute transcription system. Through our experiments, we identified TFIID and IIA as p53 functional targets (results will be discussed later), but the effect of c-Abl on the interaction of p53 with TFIID or IIA was not observed. These results, together with our results described in Specific Aim 2, suggest that c-Abl affects DNA binding activity but not p53's ability to interact with transcription machinery. During the course of these studies, we did observe that c-Abl inhibits the ability of p300 to acetylate p53 in vitro (Xing and Liu, unpublished results). The significance of this finding is currently unclear.

In the face of the disappointment in identification of the c-Abl targets, we turned our efforts to the study of SV40 T antigen. Recently, we have shown that T antigen, under certain conditions, can repress p53-dependent transcription by a mechanism in which the transactivation domain of p53 is abrogated while DNA binding is unaffected (Sheppard et al 1999). Specifically, p53 purified as a complex with T antigen from mouse cells was found to bind DNA as a transcriptionally inactive intact complex, while that purified from human cells was found to bind DNA independently of T antigen and could activate p53-dependent transcription. Thus, we proposed a model for T antigen transformation (Fig. 2, Sheppard et al, 1999). In human cells, latent p53 and T antigen form a complex that is unable to bind to DNA. Upon activation of p53, a possible conformational change in p53 allows p53 to dissociate from the p53/T complex and bind to DNA. Therefore, p53-activated transcription that is required for growth arrest and apoptosis would not be lost. In mouse cells,

again latent p53 and T antigen form a complex that does not bind DNA. Upon activation, however, the p53-T complex binds DNA as a transcriptionally inactive complex. p53 responsive promoters therefore would be completely blocked. Because SV40 T antigen is known to cause tumors in rodents but has not been shown to be a complete carcinogen in humans, we speculate that our model may provide an explanation at the molecular level. Therefore, we decided to characterize the effect of T antigen on p53-dependent transcription *in vitro* and on the interaction of p53 with its functional targets, like we proposed with c-Abl.




Figure 2. Proposed model of p53 inhibition by T antigen in mouse (m) and human (h) cells.

In Xing et al, 2001, we report that p53 stimulates transcription by enhancing the recruitment of the basal transcription factors TFIIA and TFIID on the promoter (the DA complex) and by inducing a conformational change in the DA complex. Significantly, we have demonstrated that T antigen inhibits p53-mediated transcription by blocking this ability of p53. We investigated the mechanism for this inhibition and found that the DA complex formation was resistant to T antigen repression when the TFIID-DNA complex was formed prior to the addition of the p53-T antigen complex, which indicates that the T antigen, once tethered to the promoter by p53, targets TFIID. Further, we have shown that the p53-T antigen complex prevents TBP from binding to the TATA box. Thus, these data suggest a detailed mechanism by which p53 activates transcription and by which T antigen inhibits p53-mediated transcription.

In addressing Specific Aim 4, we constructed Gal4-Abl construct and found that it is incapable of stimulating transcription from a promoter containing five Gal4 binding sites in a transient transfection assay. The results suggest that c-Abl does not function as a transcription factor and again support the notion that c-Abl affects p53-mediated transcription via enhancing its DNA binding.

In addressing Specific Aim 5, we performed in vitro phosphorylation assay using purified p53 and c-Abl and found that c-Abl is incapable of phosphorylating p53, suggesting that c-Abl does not function as a kinase to activate p53-mediated transcription. These results are in agreement with data obtained in several other labs, supporting the notion that c-Abl affects p53-mediated transcription via enhancing its DNA binding.

KEY RESEARCH ACCOMPLISHMENTS

Although it is known that c-Abl stimulates p53-dependent transcription, a function required for c-Abl growth suppressor activity, the molecular mechanism by which this occurs remain elusive. The results obtained this year show that c-Abl interacts with the C-terminal regulatory domain of tetrameric form of p53 and functions to activate the p53 DNA-binding. In an effort to assess the mechanism of c-Abl activation, we also show that c-Abl activates p53 DNA-binding by stabilizing the p53-DNA complex. Collectively, these results suggest a model for c-Abl activation. In this model c-Abl activates latent p53 by relieving the C-terminal inhibitory domain of p53 and enhances p53 DNA-binding by forming a stable p53-DNA complex.

REPORTABLE OUTCOMES

Publications:

1. Song, X.D., H.M. Sheppard, A.W. Norman and X. Liu. 1998. Mitogen-activated protein kinase is involved in the degradation of p53 protein in the bryostatin-1 induced differentiation of the acute promyelocytic leukemia cell line NB4. J. Biol. Chem. 274:1677-1682.
2. Sheppard, H.M., S.I. Corneillie, C. Espiritu, A. Gatti and X. Liu. 1999. New insights into the mechanism of inhibition of p53 by SV40 large T antigen. Mol. Cell. Biol. 19:2746-2753.
3. Ross, J.F., X. Liu and B.D. Dynlacht. 1999. Mechanism of transcription repression by the retinoblastoma tumor suppressor protein. Mol. Cell 3:195-205.
4. Sheppard, H.M. and X. Liu. 1999. Phosphorylation by DNAPK inhibits the DNA-binding function of p53/T antigen complex in vitro. Anticancer Research 19:2079-2083.
5. Nie, Y., H.-H. Li, C.M. Bula and X. Liu. 2000. Stimulation of p53 DNA-binding by c-Abl requires the p53 C-terminus and tetramerization. Mol. Cell. Biol. 20:741-748.
6. Sheppard, H.M. and X. Liu. 2000. DNA-dependent protein kinase stimulates transcription by RNA polymerase II. Biochim. Biophys. Acta. 1493:41-47.
7. Gatti, A., H.-H. Li, J.A. Traugh and X. Liu. 2000. Phosphorylation of human p53 on Thr-55. Biochemistry 39:9837-9842.
8. Xing, J., H.M. Sheppard, S.I. Corneillie and X. Liu. 2001. p53 stimulates TFIID-TFIIA-promoter complex assembly and p53-T antigen complex inhibits TATA binding protein-TATA interaction. Mol. Cell. Biol. 21:3652-3661.

CONCLUSIONS

The finding that c-Abl stimulates p53's DNA-binding via the negative regulatory domain may provide important clues about the regulation of p53. It has been suggested by other investigators that peptides designed to interact with this region can be used to reactivate p53 pathway in tumor cells to cause cell cycle arrest. In spite of the significance of this region, however, no growth regulatory protein has been shown to function directly via this region. In this study, we present results that clearly indicate a link between the growth suppressor c-Abl and p53 transcription regulation, and importantly, provide an example of activation of p53 DNA-binding activity via the carboxyl terminal regulatory domain by a cell-cycle protein.

APPENDICES

None

BIBLIOGRAPHY

Publications:

1. Liu, X. and L.S. Cheng. 1987. Effect of lipid peroxidation on hypocrellin A--photosensitized cross-linking of membrane protein. *Acta Biologiae Experimentalis Sinica* 20:373-380.
2. Liu, X., C.C. Giza and K.E. Vrana. 1990. High efficiency transient expression of eukaryotic genes: use of an HSV-1 immediate early promoter (ICP4). *Biotechniques* 9:168-173.
3. Liu, X. and K.E. Vrana. 1991. Leucine zipper and coiled-coil in the aromatic amino acid hydroxylases. *Neurochem. Int.* 18:27-31.
4. Lee, W.S., C.C. Kao, G.O. Bryant, X. Liu and A.J. Berk. 1991. Adenovirus E1A activation domain binds the basic repeat in the TATA box transcription factor. *Cell* 67:365-376.
5. Liu, X., C.W. Miller, H.P. Koeffler and A.J. Berk. 1993. The p53 activation domain binds the TATA box-binding polypeptide in holo-TFIID, and a neighboring p53 domain inhibits transcription. *Mol. Cell. Biol.* 13:3291-3300.
6. Walker, S.J., X. Liu, R. Roskoski Jr. and K.E. Vrana. 1994. Catalytic core of rat tyrosine hydroxylase: terminal deletion analysis of bacterially-expressed enzyme. *Biochim. Biophys. Acta* 1206:113-119.
7. Vrana, K.E., S.J. Walker, P. Rucker and X. Liu. 1994. A carboxyl terminal leucine zipper is required for tyrosine hydroxylase tetramer formation. *J. Neurochem.* 63:2014-20.
8. Yew, P.R., X. Liu and A.J. Berk. 1994. Adenovirus early 1B oncoprotein tethers a transcriptional repression domain to p53. *Genes & Dev.* 8:190-202.
9. Liu, X. and A.J. Berk. 1995. Reversal of in vitro p53-squelching by both TFIIB and TFIID. *Mol. Cell. Biol.* 15, 6471-6478.

10. Goga, A.*, X. Liu*, T.M. Hambuch, K. Senechal, A.J. Berk, O.N. Witte and C.L. Sawyers. 1995. p53-dependent growth suppression by the c-Abl nuclear tyrosine kinase. *Oncogene* 11:791-799. (*contributed equally).
11. Song, X.D., H.M. Sheppard, A.W. Norman and X. Liu. 1998. MAP-kinase is involved in the degradation of p53 protein in the bryostatin-1 induced differentiation of the acute promyelocytic leukemia cell line NB4. *J. Biol. Chem.* 274:1677-1682.
12. Sheppard, H.M., S.I. Corneillie, C. Espiritu, A. Gatti and X. Liu. 1999. New insights into the mechanism of inhibition of p53 by SV40 large T antigen. *Mol. Cell. Biol.* 19:2746-2753.
13. Ross, J.F., X. Liu and B.D. Dynlacht. 1999. Transcription repression by the retinoblastoma tumor suppressor protein in the absence of chromatin. *Molecular Cell* 3:195-205.
14. Sheppard, H.M. and X. Liu. 1999. Phosphorylation by DNA-dependent protein kinase inhibits the DNA-binding function of p53-T antigen complex in vitro. *Anticancer Research* 19:2079-2083.
15. Nie, Y., H.-H. Li, C.M. Bula and X. Liu. 2000. Stimulation of p53 DNA-binding by c-Abl requires the p53 C-terminus and tetramerization. *Mol. Cell. Biol.* 20:741-748.
16. Gatti, A., H.-H. Li, J.A. Traugh and X. Liu. 2000. Phosphorylation of human p53 on Thr-55. *Biochemistry* 39:9837-9842.
17. Sheppard, H.M. and X. Liu. 2000. DNA-dependent protein kinase stimulates transcription by RNA polymerase II. *Biochim. Biophys. Acta* 1493:41-47.
18. Xing, J., H.M. Sheppard, S.I. Corneillie and X. Liu. 2001. p53 stimulates TFIID-TFIIA-promoter complex assembly and p53-T antigen complex inhibits TATA binding protein-TATA interaction. *Mol. Cell. Biol.* 21:3652-3661.
19. Maeda, Y., S.D. Seidel, G. Wei, X. Liu and F.M. Sladek. 2001. Repression of hepatocyte nuclear factor 4 α by tumor suppressor p53: involvement of the ligand binding domain and histone deacetylase activity. Submitted.

20. Li, H.-H., A.G. Li, G. Wei, H.M. Sheppard and X. Liu. Phosphorylation of p53 by TAF_{II}250: possible roles in cell cycle regulation. Submitted.

Abstracts:

1. Liu, X., J. Lucci, A. Azzaro and K.E. Vrana. 1989. Expression of tyrosine hydroxylase cDNA clone using in vitro transcription and translation. *J. Cell. Biol.* 107, 507a.
2. Liu, X., R. Roskoski Jr and K.E. Vrana. 1990. Bacterial expression of tyrosine hydroxylase as beta-galactosidase fusion proteins. *The FASEB J.* 4:7, A2151.
3. Liu, X. and A.J. Berk. 1992. Interaction of p53 and TBP is necessary for p53 transactivation. Presented at the Molecular Biology of SV40, Polyoma and Adenovirus Meeting, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
4. Liu, X., P.R. Yew and A.J. Berk. 1993. Mechanism of inhibition of p53-mediated transactivation by adenovirus E1B 55K protein. Presented at the DNA Tumor Virus Meeting, Cambridge, England.
5. Liu, X. and A.J. Berk. 1994. Study of the mechanism of p53 transcriptional regulation. Presented at the 7th p53 Meeting, Ontario, Canada.
6. He, L., J. Yu, M. Xie, G. Steele-Perkins, R.T. Bronson, X. Liu, L. Liu, I. Buyse, D. Simon, G. Brodeur, and S. Huang. 1997. Induction of p53 apoptosis by the candidate tumor suppressor RIZ1. Presented at the 3rd Tumor Suppressor Meeting, Frederick, MD.
7. Liu, X. and C. Bula. 1997. Mechanism of regulation of p53-dependent transcription by c-Abl. Presented at "Era of Hope" Breast Cancer Program Annual Meeting, Washington, DC.
8. Sheppard, H.M. and X. Liu. 1998. SV40 large T antigen blocks the activation domain of p53. Presented at Keystone Symposium: Transcriptional Mechanism, Taos, NM.
9. Liu, X., H.M. Sheppard, C. Espiritu and A. Gatti. 1998. New insights into the mechanism of inhibition of p53 by SV40 large T antigen. Presented at 9th p53 Meeting, Crete, Greece.

10. Sheppard, H.M. and X. Liu. 1998. An alternative mechanism for the inhibition of p53-dependent transcription by SV40 large T antigen. Presented at the 14th Annual Meeting on Oncogenes, San Diego, CA.
11. Corneillie, S.I., J. Xing, H.M. Sheppard, L. Anton and X. Liu. 1999. Role of TAFII31 in p53-mediated stimulation of TFIIA-TFIID-complex assembly. Presented at Cold Spring Harbor Laboratory Meeting on Mechanism of Eukaryotic Transcription, Cold Spring Harbor, New York.
12. Ross, J.F., X. Liu and B.D. Dynlacht. 1999. Transcription repression by the Retinoblastoma tumor suppressor protein in the absence of chromatin. Presented at Cold Spring Harbor Laboratory Meeting on Mechanism of Eukaryotic Transcription, Cold Spring Harbor, New York.
13. Maeda, Y., X. Liu and F.M. Sladek. 1999. Nuclear receptor HNF4 interacts with tumor suppressor p53. Presented at Gordon Research Conference on Hormone Action, Meriden, NH.
14. Xing J., H.M. Sheppard, S.I. Corneillie and X. Liu. 1999. p53 stimulates TFIID-TFIIA-promoter complex formation and p53/T complex represses TBP binding to TATA box. *Mol. Biol. of the Cell*. Suppl. In Press.
15. Liu, X., Y. Nie, H.-H. Li and C.M. Bula. 2000. Stimulation of p53 DNA-binding by c-Abl requires the p53 C-terminus and tetramerization. "Era of Hope" Breast Cancer Research Program Annual Meeting, Atlanta, GA.
16. Liu, X., H.-H. Li, A. Gatti and H.M. Sheppard. 2000. Phosphorylation of human p53 at Thr-55 by TAF_{II}250. Presented at Gordon Research Conference on Molecular Genetics, New London, CT.
17. Li, H.-H., A.G. Li, H.M. Sheppard and X. Liu. 2000. Phosphorylation by TAF_{II}250 leads to the degradation of p53. Presented at Cold Spring Harbor Laboratory Meeting on Cancer Genetics and Tumor Suppressor Genes, Cold Spring Harbor, NY.
18. Maeda, Y., X. Liu and F.M. Sladek. 2001. Multiple mechanisms of suppression of a nuclear receptor by tumor suppressor protein p53: involvement of the ligand binding

domain and histone deacetylase activity. Presented at Presented at Keystone Symposium on Mechanism of Eukaryotic Transcription, Santa Fe, NM.

19. Xing, J., H.M. Sheppard, S.I. Corneillie and X. Liu. 2001. p53 stimulates TFIID-TFIIA-promoter complex assembly and p53-T antigen complex inhibits TATA binding protein-TATA interaction. Presented at Cold Spring Harbor Laboratory Meeting on Mechanism of Eukaryotic Transcription, Cold Spring Harbor, New York.

PERSONNEL

Hilary M. Sheppard, Ph.D.

Nie Ying, Ph.D.

Siska I. Corneillie, Ph.D.

Gang Wei, Ph.D.

Craig M. Bula

Henghong Li

Jun Xing

Andrew G. Li